Schizophrenia News

Pharmadax Inc. recently announced that the FDA approved a generic version of Seroquel XR tablets for schizophrenia and specific symptoms in bipolar disorder and depression.

Following a recent meeting with the FDA, Minerva Neurosciences Inc. announced updated plans for phase 3 and 4 clinical development of MIN-101 for schizophrenia.

A coordinated specialty care intervention did not reduce likelihood of receiving Social Security Administration disability benefits among individuals with first-episode schizophrenia; however, findings indicated some adverse consequences of receiving benefits.

A review conducted by experts in the field found little evidence of negative long-term effects of antipsychotics for schizophrenia and indicated significant efficacy for acute psychosis treatment and prevention of relapse.

BB0817, a 6-month risperidone implant, had comparable efficacy, safety and tolerability with oral risperidone, according to findings released by Braeburn Pharmaceuticals.

At the American Academy of Neurology annual meeting, researchers presented long-term efficacy and safety data supporting the recent FDA approval of Ingrezza for tardive dyskinesia in adults.

Recent findings indicated only smaller spines, not larger spines, were lost in deep layer 3 of the primary auditory cortex among individuals with schizophrenia.

The FDA recently approved Ingrezza capsules for treatment of tardive dyskinesia in adults.

Once monthly aripiprazole lauroxil improved social and functional outcomes among individuals hospitalized with acute schizophrenia, according to recent findings.

Recent findings indicated significantly higher mortality rates among young adults with first-episode psychosis but low rates of antipsychotic treatment and psychotherapy.